ALPHA COGNITION INC
ACOGNASDAQTrading Snapshot
- Day Range
- $8.63 – $8.80
- 52-Week Range
- $4.50 – $10.14
- Volume
- $2.66B
- Avg Volume
- $2.72B
- Shares Outstanding
- 21.8M
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- 12.2x
- EPS (TTM)
- $-1.09
- Dividend Yield
- —
- Dilution (1yr)
- +98.4%
Why Investors Own ACOG
- ✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALPHA COGNITION INC
ACOG
StockOtter · stockotter.spaceAbout ALPHA COGNITION INC
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies
Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00
Alpha Cognition Inc. (NASDAQ: ACOG - Get Free Report) has received an average rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the s
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitatin
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZU
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.